John Overdeck’s Jazz Pharmaceuticals JAZZ Stock Holding History

John Overdeck’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,600	Closed	-$1.73M	–	3472
2021 Q4	$1.73M	Sell	13,600 -25,200	-65%	-$3.31M	﹤0.01%	2053
2021 Q3	$5.05M	Buy	+38,800	New	+$5.86M	0.01%	1219
2019 Q4	–	Sell	-2,000	Closed	-$256K	–	3820
2019 Q3	$256K	Hold	2,000	–	–	﹤0.01%	3052
2019 Q2	$285K	Buy	2,000 +300	+18%	+$40.3K	﹤0.01%	2890
2019 Q1	$243K	Buy	+1,700	New	+$222K	﹤0.01%	2728
2018 Q2	–	Sell	-3,200	Closed	-$483K	–	3479
2018 Q1	$483K	Buy	+3,200	New	+$469K	﹤0.01%	2487
2017 Q4	–	Sell	-10,700	Closed	-$1.56M	–	3264
2017 Q3	$1.56M	Buy	+10,700	New	+$1.62M	0.01%	1447
2017 Q1	–	Sell	-13,000	Closed	-$1.42M	–	3101
2016 Q4	$1.42M	Buy	+13,000	New	+$1.45M	0.01%	1753

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

John Overdeck's JAZZ Position: Q2 2026 in Review

John Overdeck increased its Jazz Pharmaceuticals (JAZZ) stake by 1,942% in Q2 2026, buying an estimated $83.4M and bringing the position to 400,212 shares worth $96.4M. The position accounts for 0.07% of the portfolio, ranked #318.

John Overdeck first reported a position in JAZZ in Q2 2013 and has held it in 41 quarters since. 640 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

John Overdeck held 400,212 shares of Jazz Pharmaceuticals worth $96.4M as of Q2 2026.
John Overdeck bought 380,612 Jazz Pharmaceuticals shares in Q2 2026, an estimated $83.4M.
Jazz Pharmaceuticals made up 0.07% of John Overdeck's portfolio in Q2 2026, its #318 holding.
John Overdeck first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
640 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.